- Market Capitalization, $K 277,779
- Shares Outstanding, K 53,729
- Annual Sales, $ -70 K
- Annual Income, $ -84,710 K
- 60-Month Beta 0.02
- Price/Sales 945.78
- Price/Cash Flow N/A
- Price/Book 1.25
|Period||Period Low||Period High||Performance|
| || |
+4.21 (+157.68%)since 11/06/23
| || |
+4.39 (+176.31%)since 09/06/23
| || |
-3.42 (-33.20%)since 12/06/22
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP
The stock recently fell around 25% for reasons that had nothing to do with its lead program.
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate....
It's not the end of the story for this once high-flying biotech stock.
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.